Drug Profile
Research programme: AMPK activators - NovaTarg Therapeutics
Alternative Names: NT 1044Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator NovaTarg Therapeutics
- Class Antineoplastics; Biguanides
- Mechanism of Action AMP activated protein kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Dengue; Fatty liver; Hepatitis C; Polycystic kidney disease; Type 2 diabetes mellitus
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 28 Jun 2020 No recent reports of development identified for research development in Dengue in USA
- 28 Jun 2020 No recent reports of development identified for research development in Fatty liver in USA